PARP cleavage and caspase activity to assess chemosensitivity.
The ultimate aim of cancer therapeutics is to eradicate tumor cells. Upon lethal exposure to chemotherapeutic agents, cells undergo apoptosis an active, energy-requiring, programmed cell death. Apoptosis follows a well-orchestrated activation of cysteine proteases, known as caspases. In normal conditions, all the caspases exist as inactive procaspases; they require proteolytic cleavage for activation. A variety of methods are currently used to detect procaspases and caspases and their activity. Immunodetection and fluorescent substrates are widely accepted methods that are utilized for this purpose. These methods are described in detail in this chapter.
Bharti
Alok C
AC
Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Takada
Yasunari
Y
Aggarwal
Bharat B
BB
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D015153:Blotting, Western; D020169:Caspases / Q000378:metabolism*; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D003474:Curcumin / Q000494:pharmacology; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D008856:Microscopy, Fluorescence / Q000379:methods*; D010455:Peptides / Q000494:pharmacology; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism*; D013997:Time Factors
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D010455:Peptides; D011065:Poly(ADP-ribose) Polymerases; D020169:Caspases; D003474:Curcumin